S. H. Swerdlow, E. Campo, and S. A. Pileri, The 2016 revision of the World Health Organization classification of lymphoid neoplasms, Blood, vol.127, issue.20, pp.2375-2390, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01800015

L. Brugieres, L. Deley, M. C. Rosolen, and A. , Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: results of a randomized trial of the EICNHL Group, J Clin Oncol, vol.27, issue.6, pp.897-903, 2009.

S. W. Morris, M. N. Kirstein, and M. B. Valentine, Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma, Science, vol.263, issue.5151, pp.1281-1284, 1994.

G. Delsol, B. Falini, . Mûller-hermelink, . Hk, and E. Campo, Anaplastic large cell lymphoma, ALK-positive, 2008.
URL : https://hal.archives-ouvertes.fr/hal-00611903

T. Iwahara, J. Fujimoto, and D. Wen, Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system, Oncogene, vol.14, issue.4, pp.439-449, 1997.

C. Damm-welk, K. Busch, and B. Burkhardt, Prognostic significance of circulating tumor cells in bone marrow or peripheral blood as detected by qualitative and quantitative PCR in pediatric NPM-ALK-positive anaplastic large-cell lymphoma, Blood, vol.110, issue.2, pp.670-677, 2007.

K. Ait-tahar, C. Damm-welk, and B. Burkhardt, Correlation of the autoantibody response to the ALK oncoantigen in pediatric anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with tumor dissemination and relapse risk, Blood, vol.115, issue.16, pp.3314-3319, 2010.

R. Chiarle, C. Voena, C. Ambrogio, R. Piva, and G. Inghirami, The anaplastic lymphoma kinase in the pathogenesis of cancer, Nat Rev Cancer, vol.8, issue.1, pp.11-23, 2008.

S. R. Mcdonnell, S. R. Hwang, and V. Basrur, NPM-ALK signals through glycogen synthase kinase 3beta to promote oncogenesis, Oncogene, vol.31, issue.32, pp.3733-3740, 2012.

A. Wellmann, V. Doseeva, and W. Butscher, The activated anaplastic lymphoma kinase increases cellular proliferation and oncogene up-regulation in rat 1a fibroblasts, FASEB J, vol.11, issue.12, pp.965-972, 1997.

V. Leventaki, E. Drakos, and L. J. Medeiros, NPM-ALK oncogenic kinase promotes cellcycle progression through activation of JNK/cJun signaling in anaplastic large-cell lymphoma, Blood, vol.110, issue.5, pp.1621-1630, 2007.

T. L. Gu, Z. Tothova, B. Scheijen, J. D. Griffin, D. G. Gilliland et al., NPM-ALK fusion kinase of anaplastic large-cell lymphoma regulates survival and proliferative signaling through modulation of FOXO3a, Blood, vol.103, issue.12, pp.4622-4629, 2004.

A. Fernandez-vidal, A. Mazars, E. F. Gautier, G. Prevost, B. Payrastre et al., Upregulation of the CDC25A phosphatase down-stream of the NPM/ALK oncogene participates to anaplastic large cell lymphoma enhanced proliferation, Cell Cycle, vol.8, issue.9, pp.1373-1379, 2009.

M. J. Bueno and M. Malumbres, MicroRNAs and the cell cycle, Biochim Biophys Acta, vol.1812, issue.5, pp.592-601, 2011.

R. Garzon, G. A. Calin, and C. M. Croce, MicroRNAs in Cancer, Annu Rev Med, vol.60, pp.167-179, 2009.

C. Hoareau-aveilla, O. Merkel, and F. Meggetto, MicroRNA and ALK-positive anaplastic large cell lymphoma, Front Biosci (Schol Ed), vol.7, pp.217-225, 2015.

C. Hoareau-aveilla, T. Valentin, and C. Daugrois, Reversal of microRNA-150 silencing disadvantages crizotinib-resistant NPM-ALK(+) cell growth, J Clin Invest, vol.125, issue.9, pp.3505-3518, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01614947

O. Merkel, G. Robert, F. Hamacher, L. Grabner, R. Greil et al., Subtype specific expression of immnune-modulating miR-155 and miR-146a in anaplastic large cell lymphoma, Cancer Res, vol.72, issue.8, p.1, 2009.

E. Dejean, M. H. Renalier, and M. Foisseau, Hypoxia-microRNA-16 downregulation induces VEGF expression in anaplastic lymphoma kinase (ALK)-positive anaplastic large-cell lymphomas, Leukemia, vol.25, issue.12, pp.1882-1890, 2011.
DOI : 10.1038/leu.2011.168
URL : https://hal.archives-ouvertes.fr/hal-00611903

C. Desjobert, M. H. Renalier, and J. Bergalet, MiR-29a down-regulation in ALK-positive anaplastic large cell lymphomas contributes to apoptosis blockade through MCL-1 overexpression, Blood, vol.117, issue.24, pp.6627-6637, 2011.
DOI : 10.1182/blood-2010-09-301994
URL : https://hal.archives-ouvertes.fr/hal-00611908

A. Congras, N. Caillet, and N. Torossian, Doxorubicin-induced loss of DNA topoisomerase II and DNMT1-dependent suppression of MiR-125b induces chemoresistance in ALK-positive cells, Oncotarget, vol.9, issue.18, pp.14539-14551, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01815723

X. X. He, S. Z. Kuang, and J. Z. Liao, The regulation of microRNA expression by DNA methylation in hepatocellular carcinoma, Mol Biosyst, vol.11, issue.2, pp.532-539, 2015.

G. Yang, G. Xiong, and Z. Cao, miR-497 expression, function and clinical application in cancer, Oncotarget, vol.7, issue.34, pp.55900-55911, 2016.

J. R. Finnerty, W. X. Wang, S. S. Hebert, B. R. Wilfred, G. Mao et al., The miR-15/107 group of microRNA genes: evolutionary biology, cellular functions, and roles in human diseases, J Mol Biol, vol.402, issue.3, pp.491-509, 2010.

M. V. Iorio, P. Casalini, E. Tagliabue, S. Menard, and C. M. Croce, MicroRNA profiling as a tool to understand prognosis, therapy response and resistance in breast cancer, Eur J Cancer, vol.44, issue.18, pp.2753-2759, 2008.

Y. Pikman, G. Alexe, and G. Roti, Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia, Clin Cancer Res, vol.23, issue.4, pp.1012-1024, 2017.

C. M. Sawai, J. Freund, and P. Oh, Therapeutic targeting of the cyclin D3:CDK4/6 complex in T cell leukemia, Cancer Cell, vol.22, issue.4, pp.452-465, 2012.

L. Lamant, E. Espinos, and M. Duplantier, Establishment of a novel anaplastic largecell lymphoma-cell line (COST) from a 'small-cell variant' of ALCL, Leukemia, vol.18, issue.10, pp.1693-1698, 2004.

C. A. Schneider, W. S. Rasband, and K. W. Eliceiri, NIH Image to ImageJ: 25 years of image analysis, Nat Methods, vol.9, issue.7, pp.671-675, 2012.

M. A. Thompson, J. Stumph, and S. E. Henrickson, Differential gene expression in anaplastic lymphoma kinase-positive and anaplastic lymphoma kinase-negative anaplastic large cell lymphomas, Hum Pathol, vol.36, issue.5, pp.494-504, 2005.

S. Nagel, E. Leich, and H. Quentmeier, Amplification at 7q22 targets cyclin-dependent kinase 6 in T-cell lymphoma, Leukemia, vol.22, issue.2, pp.387-392, 2008.
DOI : 10.1038/sj.leu.2405028
URL : https://www.nature.com/articles/2405028.pdf

T. Degenhardt, R. Wuerstlein, T. Eggersmann, and N. Harbeck, The safety of palbociclib for the treatment of advanced breast cancer, Expert Opin Drug Saf, vol.28, pp.1-6, 2018.

J. F. He, Y. M. Luo, X. H. Wan, and D. Jiang, Biogenesis of MiRNA-195 and its role in biogenesis, the cell cycle, and apoptosis, J Biochem Mol Toxicol, vol.25, issue.6, pp.404-408, 2011.

J. Steinhilber, M. Bonin, M. Walter, F. Fend, I. Bonzheim et al., Nextgeneration sequencing identifies deregulation of microRNAs involved in both innate and adaptive immune response in ALK+ ALCL, PLoS One, vol.10, issue.2, p.117780, 2015.

X. Liu, X. Chen, and X. Yu, Regulation of microRNAs by epigenetics and their interplay involved in cancer, J Exp Clin Cancer Res, vol.32, p.96, 2013.

H. Deng, Y. Guo, and H. Song, MicroRNA-195 and microRNA-378 mediate tumor growth suppression by epigenetical regulation in gastric cancer, Gene, vol.518, issue.2, pp.351-359, 2013.

W. Li, J. X. Deng, X. Zhang, G. Zhang, B. Ma et al., The putative tumor suppressor microRNA-497 modulates gastric cancer cell proliferation and invasion by repressing eIF4E, Biochem Biophys Res Commun, vol.449, issue.2, pp.235-240, 2014.

Q. Luo, X. Li, and Y. Gao, MiRNA-497 regulates cell growth and invasion by targeting cyclin E1 in breast cancer, Cancer Cell Int, vol.13, issue.1, p.95, 2013.

M. Furuta, K. Kozaki, and K. Tanimoto, The tumor-suppressive miR-497-195 cluster targets multiple cell-cycle regulators in hepatocellular carcinoma, PLoS One, vol.8, issue.3, p.60155, 2013.

Y. Zhang, Z. Zhang, and Z. Li, MicroRNA-497 inhibits the proliferation, migration and invasion of human bladder transitional cell carcinoma cells by targeting E2F3, Oncol Rep, vol.36, issue.3, pp.1293-1300, 2016.

D. M. Ozata, S. Caramuta, and D. Velazquezfernandez, The role of microRNA deregulation in the pathogenesis of adrenocortical carcinoma, Endocr Relat Cancer, vol.18, issue.6, pp.643-655, 2011.

J. W. Xu, T. X. Wang, and L. You, Insulin-like growth factor 1 receptor (IGF-1R) as a target of MiR-497 and plasma IGF-1R levels associated with TNM stage of pancreatic cancer, PLoS One, vol.9, issue.3, p.92847, 2014.

L. Shen, J. Li, and L. Xu, miR-497 induces apoptosis of breast cancer cells by targeting Bcl-w, Exp Ther Med, vol.3, issue.3, pp.475-480, 2012.

K. Kollmann, G. Heller, and C. Schneckenleithner, A kinase-independent function of CDK6 links the cell cycle to tumor angiogenesis, Cancer Cell, vol.24, issue.2, pp.167-181, 2013.

A. J. Ferreri, S. Govi, S. A. Pileri, and K. J. Savage, Anaplastic large cell lymphoma, ALK-positive, Crit Rev Oncol Hematol, vol.83, issue.2, pp.293-302, 2012.

X. Agirre, A. Vilas-zornoza, and A. Jimenezvelasco, Epigenetic silencing of the tumor suppressor microRNA Hsa-miR124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia, Cancer Res, vol.69, issue.10, pp.4443-4453, 2009.

L. H. Oliveira, J. L. Schiavinato, and M. S. Fraguas, Potential roles of microRNA-29a in the molecular pathophysiology of T-cell acute lymphoblastic leukemia, Cancer Sci, vol.106, issue.10, pp.1264-1277, 2015.

M. G. Hu, A. Deshpande, and M. Enos, A requirement for cyclin-dependent kinase 6 in thymocyte development and tumorigenesis, Cancer Res, vol.69, issue.3, pp.810-818, 2009.

L. B. Baughn, D. Liberto, M. Wu, and K. , A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6, Cancer Res, vol.66, issue.15, pp.7661-7667, 2006.

P. Bonvini, E. Zorzi, and L. Mussolin, The effect of the cyclin-dependent kinase inhibitor flavopiridol on anaplastic large cell lymphoma cells and relationship with NPM-ALK kinase expression and activity, Haematologica, vol.94, issue.7, pp.944-955, 2009.